pembrolizumab plus axitinib trial
Phase 2
Recruiting
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-jRCT1061200062
- Lead Sponsor
- Takehiro Iawata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 7
Inclusion Criteria
Patients of unresectable or metastatic non-clear cell renal carcinoma without history of drug treatment.
Exclusion Criteria
Karnofsky performance-status<70
Patients with autoimmune disease.
Patients with ischemic heart disease or New York Heart Association class 3 or 4 heart failure within the past year.
Patients receiving dialysis treatment.
Patients with a history of hypersensitivity for pembrolizumab or axitinib.
Pregnant patients.
Patients with liver dysfunction for Child- Pugh score B or C.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method